A study to investigate efficacy and safety of Infusion regimen compared with placebo in participants 16 to 25 years of age with Stage 3 Type 1 Diabetes.

• Aged 16 to 25 years of age inclusive

• Diagnosed with Type 1 Diabetes Stage 3 within 8 weeks

Further qualifications apply: Must be positive for at least one Type 1 Diabetes autoantibody at screening

Gain access to cutting-edge medications and treatments before they are widely available.

Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.

We are highly focused on patient well-being and the highest ethical standards in clinical research.